Physician profile
Casey Mclaughlin
NPI 1558110312
$670.48
in general payments reported to CMS, 2019-2025
22 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $554 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $82.38 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $53.34 | 2024 | Abilify Mycite |
| Novo Nordisk INC | $52.96 | 2024 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $51.60 | 2024 | Onpattro |
| Aimmune Therapeutics, INC. | $45.90 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.78 | 2024 | |
| Sumitomo Pharma America, INC. | $36.10 | 2024 | Gemtesa |
| Edwards Lifesciences Corporation | $35.34 | 2025 | |
| Glaxosmithkline, LLC. | $26.56 | 2024 | Trelegy Ellipta |
| Medtronic, INC. | $26.42 | 2024 | Minimed 780g |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.74 | 2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $22.23 | 2025 | Camzyos |
| Hologic Sales and Service, LLC | $21.26 | 2025 | Aptima, Thinprep 2000 Processor |
| Lucid Diagnostics INC. | $19.74 | 2025 | |
| Lundbeck LLC | $19.52 | 2024 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rgh Enterprises LLC | $18.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $17.72 | 2024 | Airsupra |
| Cequr Corporation | $17.46 | 2024 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $16.80 | 2024 | Nexletol |
| Biogen, INC. | $15.45 | 2024 | Skyclarys |
| Takeda Pharmaceuticals U.S.A., INC. | $14.78 | 2024 | Trintellix |
| Xeris Pharmaceuticals, INC. | $13.40 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.